The ferroxidase HEPHaestin in Lung cancer: Pathological Significance and Prognostic Value

- 2 Paola Zacchi¹, Beatrice Belmonte², Alessandro Mangogna³, Gaia Morello², Letizia Scola⁴, Anna
- 3 Martorana², Violetta Borelli^{1*}
- 4 ¹Department of Life Sciences, University of Trieste, Trieste, Italy
- 5 ²Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy
- 6 ³Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy
- ⁴ Clinical Pathology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of
 Palermo, 90100 Palermo, Italy.
- 9 *Corresponding author:
- 10 Borelli Violetta
- 11 <u>borelliv@units.it</u>
- 12

1

Keywords: Hephaestin, iron metabolism, lung cancer, tumor microenvironment, stromal cells, immune infiltrate

15

16 Abstract

Iron is a fundamental nutrient utilized by living cells to support several key cellular processes. 17 Despite its paramount role to sustain cell survival, excess of labile iron availability can inflict severe 18 cell damage via reactive oxygen species generation which, in turn, can promote neoplastic 19 transformation. The lung is particularly sensitive to iron-induced oxidative stress, given the high 20 oxygen tensions herein present. Moreover, cigarette smoke as well as air pollution particulate can 21 22 function as vehicles of iron supply, leading to an iron dysregulation condition shown to be crucial in the pathogenesis of several respiratory diseases including lung cancer. Hephaestin (HEPH) belongs 23 to a group of exocytoplasmic ferroxidases emerged to contribute to cellular iron homeostasis by 24 favouring its export. Although HEPH can affect the concentration of intracellular iron labile pool, its 25 expression in lung cancer and its influence on prognosis have not been investigated. 26

In this study we explored the expression pattern and prognostic value of HEPH in the most prevalent histotypes of lung cancers including lung adenocarcinoma and lung squamous cell carcinoma across in silico analyses using UALCAN, Gepia and Kaplan-Meier plotter bioninformatics. We took advantage of TIMER to assess the correlation between HEPH and tumour infiltrating immune and non-immune cells. Then we performed immunohistochemical analysis to dissect the presence of HEPH either in "healthy" and tumor lung tissues. Overall, our data suggest a positive correlation between higher level of HEPH expression with a favorable prognosis in both cancer histotypes.

34 Introduction reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Lung cancer represents the most frequent malignant neoplasm in most countries and the 35 leading cause of death worldwide in both sexes (1). The incidence of lung cancer is low in people 36 aged below 40 years but it dramatically increases up to age 60-65 years in most populations. The 37 most common subtype of lung cancer is non-small cell lung cancer (NSCLC; 85%), classified into 38 lung adenocarcinoma (LUAD), the most prevalent form, followed by lung squamous cell carcinoma 39 (LUSC) and large cell carcinoma (2). Smoking status is certainly the most important causative link 40 in lung cancer development even though air pollution represents another paramount source of risk 41 factor. Airborne Particulate matter (PM), in particular the small size components (PM₁₀, PM_{2.5} and 42 43 ultrafine particles-UFP), which include combustion products, soot, exhaust emission from vehicles and industrial processes, have attracted attention mainly for two reasons: firstly, these particles, due 44 to their small size, remain suspended in the air for quite a long time, thus increasing the chance of 45 being inhaled; secondly, these particles are vehicles of chemical compounds, in particular transition 46 47 metals, being iron present in significant concentration (3). Iron is also found in cigarette smoke, the strongest causative link to pulmonary pathology. 48

49 Iron toxicity relies on its high redox cycling reactivity which can drive the production of free radical species (ROS) known to promote many aspects of tumour development and progression (4). 50 The lung is extremely sensitive to metal-induced oxidative stress due to its unique role for massive 51 oxygen transfer into the bloodstream (5). Therefore, as a protective strategy to prevent ROS 52 generation, lung epithelial cells have evolved a tight control on iron import, storage and export aimed 53 at keeping its absolute concentration low, while sustaining the metabolic demand (6 REF Ghio 2009). 54 Efficient iron uptake and intracellular sequestration can limit its toxicity but long-term storage can 55 increase the probability of its possible mobilization, resulting in oxidative cell damage. Iron export 56 mechanisms are therefore necessary to prevent its excessive intracellular accumulation, as it may 57 occur upon exogenous iron supply via airborne pollutants inhalation. The only known non-heme iron 58 export pathway relies on the activity of the transmembrane ferrous iron transporter ferroportin 1 59 (FPN1) also known as solute carrier family 40 member 1 (SLC40A1) (7) in conjunction with the large 60 membrane-anchored copper-dependent ferroxidase (FOX) Hephaestin (HEPH), required to oxidized 61 iron to its ferric form (8). In enterocytes FPN1 allows the translocation of iron across the basolateral 62 membrane and its release into the bloodstream (9). In lung FPN1 is, instead, mainly expressed in the 63 apical membrane of the airway epithelium (10) where it is supposed to promote iron release into the 64 airways or the lumen of the alveoli to meet the need of detoxification. This egress pathway has been 65 shown to be compromised in diverse types of cancers (11). In particular FPN1 mRNA expression 66 levels appeared significantly down-regulated in lung tumour as compared to matched healthy tissue, 67 a condition that is expected to guarantee an increase in the intracellular labile iron pool necessary for 68

all metabolic processes involved in cell proliferation (12). The role played by HEPH in iron 69 metabolism in lung is still poorly characterized as well as its possible contribution to lung 70 carcinogenesis and growth. We recently identified a single-nucleotide polymorphism within HEPH 71 gene, leading to a missense variation of this multicopper ferroxidase, which results protective against 72 asbestos-dependent malignant pleural mesothelioma and lung carcinoma (13, 14). Moreover, in breast 73 cancer HEPH expression has been shown to be down-regulated by the histone methyltransferase G9a, 74 75 leading to changes in iron homeostasis that burst cancer growth (15). In the current study, we examined the expression and prognostic value of HEPH expression 76

in LUAD and LUSC patients in databases such as UALCAN, GEPIA and Kaplan-Meier plotter.
Moreover, we investigated the correlation of HEPH expression with tumour-infiltrating immune and
non-immune cells characterizing the tumour microenvironment via Tumour Immune Estimation
Resource (TIMER). Finally, we evaluated the distribution of endogenous HEPH in lung cancer
tissues. These data altogether further support the key role played by iron dysregulation in the
carcinogenic mechanism of lung malignancies

84 Materials and Methods

85

86 Gene expression and Survival analysis

Our analysis focused on the prognostic effect of *HEPH* gene in lung adenocarcinoma (LUAD) 87 and in lung squamous cell carcinoma (LUSC). The expression level of the gene in different 88 UALCAN (http://ualcan.path.uab.edu) 89 carcinomas was analyzed using and GEPIA (http://gepia.cancer-pku.cn). Those tools estimate the effect of gene expression level on the patient 90 survival in addition to be a web resource for analyzing cancer transcriptome data (16, 17). We 91 compared the differences in mRNA level between cancers and normal tissue, using genomics data 92 from "The Cancer Genome Atlas" (TCGA lung). The prognostic significance of HEPH mRNA 93 expression and survival in LUAD and LUSC were analyzed by Kaplan Meier plotter 94 (https://kmplot.com/analysis). Kaplan Meier plotter use genomics data from Gene Expression 95 96 Omnibus, and European Genome-phenome Archive to generate survival probability plots and to perform survival analysis (2, 3). The same analysis was done for other genes (ACTA2, FAP, 97 98 PDGFRA, PDGFRB, PECAM1, vWF). The hazard ratio with 95% confidence intervals and log-rank *p*-value were also computed. . 99

100

101 **Protein Expression Analysis**

The expression HEPH proteins between cancer and normal tissue were analyzed using UALCAN, which provided protein expression analysis option using data from Clinical Proteomic Tumor Analysis Consortium (CPTAC) Confirmatory/Discovery dataset (4). Unfortunately, at the time of writing, UALCAN tool provided data only for LUAD histotype.

106

107 TIMER Database Analysis

TIMER is a comprehensive resource for systematic analysis of immune infiltrates across diverse 108 cancer types (www.cistrome.shinyapps.io/timer/) (18). TIMER applies a statistical method to infer 109 the abundance of tumor-infiltrating immune cells (TIICs) from gene expression profiles using data 110 from the TCGA dataset (19). We analyzed HEPH expression in lung cancers and the correlation 111 between its expression with the abundance of immune infiltrates, including B cells, CD4+ T cells, 112 CD8+ T cells, neutrophils, macrophages, cancer associated fibroblasts and endothelial cells via gene 113 114 modules. These gene markers are referenced in prior studies (7, 8). Gene expression levels against tumor purity are also displayed (20, 21). The correlation module generated the expression scatter 115 plots between several genes and defined genes of TIICs in chosen carcinomas, together with the 116 Spearman's correlation and the estimated statistical significance. Several genes were used for the x-117

axis, and related marker genes are represented on the y-axis as genes of TIICs. The gene expressionlevel was displayed with log2 RSEM.

120

121 Statistical Analysis

Survival curves were generated by the Kaplan Meier plotter (22). All results are displayed with pvalues from a log-rank test. p-values < 0.05 were considered significant. In TIMER, the correlation of gene expression was evaluated by Spearman's correlation and statistical significance, and the strength of the correlation was determined using the following guide for the absolute value: 0.00 -0.19 "very weak," 0.20 - 0.39 "weak," 0.40 - 0.59 "moderate," 0.60 - 0.79 "strong," 0.80 - 1.0 "very strong".

128

129 Immunohistochemistry analysis on tumour tissues

All tissue samples of lung adenocarcinoma and lung squamous cell carcinoma enrolled for this 130 study were collected according to the Helsinki Declaration and the study was approved by the 131 University of Palermo Ethical Review Board (approval number 09/2018). Surgical normal tissue 132 133 samples of lung and the malignant counterpart were selected for immunohistochemical analysis for HEPH expression. Invasive malignant neoplasia specimens included the two more represented 134 histotypes including LUAD and LUCS. The study was approved by the Institutional review board of 135 the University of Palermo (09/2018). A specific informed consent was not required at the time of tissue 136 sample collection for the immunohistochemical analysis of archival tissue sections since the patients 137 were not identified and genetic analysis was not carried out. 138

Immunohistochemistry was carried out on FFPE human tissue sections. Briefly, sections 4 139 micron-thick were cut from paraffin blocks, dried, de-waxed and rehydrated. The antigen unmasking 140 technique was performed using Target Retrieval Solutions, pH=9 EDTA-based buffer in thermostatic 141 142 bath at 98°C for 30 minutes. After the sections were brought at room temperature, the neutralization of the endogenous peroxidase with 3% H₂O₂ and protein blocking by a specific protein block were 143 performed. For HEPH immunostaining, sections were probed with mouse monoclonal anti-human 144 HEPH (Diluition 1:100, pH 6, Clone sc-365365 Santa Cruz Biotecnology) overnight at 4°C. Antibody-145 Antigen recognition was detected using Novolink Polymer Detection Systems (Novocastra Leica 146 Biosystems, Newcastle) and employing the high sensitivity AEC (3-Amino9-Ethylcarbazole) as 147 chromogen. Slides were counterstained with Harris Haematoxylin (Novocastra, Ltd). 148

All the sections were analyzed under Zeiss Axio Scope A1 optical microscope (Zeiss, Germany) and
 microphotographs were collected using an Axiocam 503 Color digital camera with the ZEN2 imaging
 software (Zeiss Germany).

152

153 **RESULTS**

154

The mRNA Expression Levels of HEPH in Different Types of Human Cancers

The ferroxidase HEPH has recently emerged to play a role in breast tumour cell growth; in 155 particular its decreased expression has been significantly correlated with a poor survival in affected 156 patients (15). In order to expand the analysis to other cancer types we examined HEPH expression 157 using UALCAN that analyse TCGA RNA-sequencing and patients' clinical data from 33 different 158 cancer types, including several metastatic tumors (22). This analysis unveiled that a significant down-159 regulation of the HEPH mRNA expression levels is found in several other malignancies such as 160 BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), COAD (colon 161 adenocarcinoma), KICH (kidney chromophobe), KIRP (kidney renal clear cell carcinoma), LIHC 162 (liver hepatocellular carcinoma), LUAD (lung adenocarcinoma), LUSC (lung squamous 163 adenocarcinoma), PRAD (prostate adenocarcinoma), READ (rectum adenocarcinoma), and UCEC 164 (uterine corpus endometrial carcinoma) compared to the corresponding normal tissues (Fig. 1A). 165

Given our interest in better understanding the role iron's dysregulation may exert in lung cancer development and prognosis, we evaluated HEPH mRNA expression levels in the most prevalent histological types LUAD and LUSC, as compared to normal tissue, utilizing the GEPIA database. Consistently with the previous analysis, a significant decrease in HEPH mRNA expression was found in LUAD and LUSC, as compared to healthy controls (Fig. 1B) and this reduction was confirmed at the protein level only for LUAD histotype, based on UALCAN dataset (Fig. 1C), since corresponding proteomic data for LUSC are still not available.

To investigate the correlation between HEPH expression and patients'outcome we took advantage of the Kaplan-Meier overall survival curves to establish and compare the survival differences between patients with high and low expression of the ferroxidase (grouped according "Auto select best cutoff") (Fig. 1D). In both LUAD and LUSC datasets, the high expression group had a significantly longer overall survival than the low expression group, thus indicating that higher HEPH expression correlates with a better prognosis.

180 181

HEPH expression is correlated with immune and non-immune infiltration

It is well established that cancer cells are characterized by an iron-seeking phenotype, which 182 is fundamental to support the enhanced metabolic demand characteristic of actively proliferating cells 183 184 (23). This increased request of iron supply is achieved not only upon up-regulating iron import pathways while down-regulating storage and export routes but also by altering how other cell types 185 of the tumor microenvironment, including immune cells, endothelial cells, pericytes and fibroblasts, 186 metabolize iron. We therefore assessed the correlations of HEPH expression with immune and non-187 immune infiltration levels using TIMER web resource (22). In particular, we assessed, as immune 188 infiltrate, B cells, CD4+ T cells, CD8+ T cells, macrophages and dendritic cells while cancer 189 associated fibroblasts and endothelial cells were analysed as infiltrating non-immune cell types. The 190 results showed that HEPH expression had a significant negative correlation with tumour purity, the 191 parameter identifying the proportion of cancer cells present in the tumour tissue, in both type of lung 192 193 cancers (Figure 2). In addition, HEPH expression demonstrated a very weak correlation with all infiltrating immune elements tested (Table 1), while a strong positive correlation was found only with 194 195 cancer associated fibroblasts (CAFs) and endothelial cells (ECs) (Figure 2).

CAFs are the most abundant cells in solid cancer. They can derived from several sources 196 including activation of resident fibroblasts (24), epithelial-mesenchymal transition of epithelial cells 197 (25), endothelial-mesenchymal transition of resident endothelial cells (26). Compared to normal 198 199 fibroblasts they are characterized by enhanced proliferative and migratory features, and they are also more metabolically active. Tumour endothelial cells refers to the cells lining the tumour-associated 200 blood vessels that provide nutrition and oxygen to the tumour, contributing to its growth and 201 development. They also constitute one of the main sources of cancer-associated fibroblasts (CAFs). 202

203 To further characterized the relationship between HEPH and these infiltrating cells in lung malignancies we explore the correlation between HEPH and a list of marker sets known to be widely 204 used to identified CAFs and ECs, using the TIMER Gene Correlation module. In particular we used 205 206 α -SMA (ACTA2, marker also for vascular muscular cells and pericytes), fibroblasts activation protein (FAP, also expressed in a subset of CD45+ immune cells), plateled-derived growth factor 207 receptor- α/β (PDGFRA/B) as biological markers for CAFs (Figure 3A); PECAM1 (CD31) and von 208 Willebrand Factor (vWF) as markers for the endothelial cells (Figure 3B). After the correlation 209 adjustment by tumour purity, HEPH expression level was significantly correlated with all marker sets 210 tested (Figure 3). 211

Interestingly we also found that the mRNA expression level of all these marker genes, with 212 213 the only exception of FAP, were significantly down-regulated in both lung malignancies as compared with paired normal tissues, based on GEPIA datasets (Figure 4A). Moreover, Kaplan Meier analysis 214

indicated that high expression of ACTA2 and PDGFRA as well as PECAM1 and vWF wereassociated with better overall survival, as it is for HEPH expression (Figure 4B).

217

218 Distribution of HEPH in clinical LUAD and LUSC specimens

Based on the results obtained upon TIMER database analysis we aimed at better understanding 219 the distribution of the HEPH in a series of specimens of LUAD and LUSC upon ferroxidase 220 221 immunohistochemical labeling. As shown in Figure 5 panel A and B, the ferroxidase staining was quite intense on endothelial cells surrounding the vasculature in peri-tumour tissues, being endothelial 222 cells and possibly perycites immunoreactive for HEPH primary antibody. HEPH was also associated 223 to macrophages, as identified by their spherical appearance and by the presence of a reniform nucleus, 224 225 and neutrophils based on their small round shape and on a clearly identifiable multi-lobed nucleus (Figure 5B, see arrows). 226

In cancer tissues HEPH distribution appeared quite different in the two malignancies 227 analyzed. In particular, in LUAD specimens we noticed that tumoral cells were totally lacking HEPH 228 expression while the very few cells HEPH positive infiltrating the cancerous tissue were characterized 229 by either a neutrophil-like or a spindle-like fibroblast morphology (Figure 6, panels B and D). There 230 were also some macrophages immune-labeled, identified based on their morphological features. In 231 LUSC, instead, we observed that about 30% of cancer cells, identified for their characteristic large 232 polygonal shape, were positive, to variable extent, for HEPH labeling (Figure 7, panel B). Moreover, 233 the tumour mass was massively infiltrated by HEPH-expressing cellular elements of neutrophil-like 234 morphology and possibly also some monocyte/macrophages (Figure 7, panels A and C). There were 235 236 also a consistent amount of HEPH positive mesenchymal cells exhibiting spindle-shaped morphology and recognized as fibroblastic stromal component (Figure 7, panels D). 237

These immune-labeling experiments, in agreement with the bioinformatics analysis, confirm the expression of HEPH by stromal elements infiltrating the tumor microenvironment and endothelial cells; in addition we clearly detected expression of the ferroxidase in cellular elements belonging to the innate-immunity, such as macrophages and neutrophils, as identified based on morphological features.

- 243
- 244

245 Discussion

Lung cancer still represent the leading cause of cancer-related deaths both in men and women, 246 especially in developed countries. Lung adenocarcinoma is the most common histologic subtype, 247 whose incidence has dramatically arose and overcome that of squamous cell carcinoma due to an 248 increase in the incidence of lung cancer in women. Despite advances in diagnosis and treatments, the 249 overall 5-year survival rate remains dismal especially when lung cancer is diagnosed at advanced 250 stages (27). Therefore, a better understanding of the molecular mechanisms underlying lung 251 carcinogenesis should contribute to the development of novel strategies for its preventions and 252 therapy. Cigarette smoking represents the principal risk factor for lung cancer, but inhalation of air 253 pollutants is also accountable for the increased incidence of this type of malignancies. Air pollution 254 and tobacco smoking have been shown to impact on lung iron metabolism, being the source of 255 additional iron supply on a tissue which is physiologically exposed to oxidative stress. In the present 256 studies we identified HEPH, a protein involved in exporting iron out from the cell, as promising 257 258 predictor for the clinical prognosis in lung cancer.

HEPH is a multi-copper oxidase whose function has been better characterized in small 259 260 intestine, where it is required for iron egress from the enterocyte into the circulatory system. HEPH is thought to work in concert with Ferroportin (FPN1), the only known mammalian iron exporter for 261 262 non-heme iron, whose down-regulation has been monitored in several cancers and it is usually correlated to a poor prognosis (12). FPN1 reduction is thought to act by increasing the concentration 263 of the intracellular labile iron pool, the catalytic/reactive iron, which, on one side, is required to 264 sustain the high metabolic demand of actively proliferating cells, but, on the other hand, it can trigger 265 the production of free radical species, further boosting the oxidative damage. In lung FPN1 is facing 266 the lumen of the alveoli and this localization has been attributed to a role in iron detoxification (10). 267 Indeed, environmental iron arriving to the lung epithelium can be initially buffered by the activity of 268 the antioxidant molecules such as ascorbic acid, reduced glutathione, and mucin, and once loaded on 269 transferrin and lactoferrin herein present, it can undergo transferrin receptor 1 (TfR1) and lactoferrin 270 271 receptor (LfR) internalization by epithelial alveolar cells and alveolar macrophages and be safely stored bound to ferritin (28). Under iron overload condition the excess of pulmonary iron can be 272 release into the lumen of the alveoli via FPN1 permease and possibly oxidize by GPI-anchored or 273 soluble ceruloplasmin, an HEPH homologue ferroxidase (29). Based on our immunohistochemical 274 localization studies, HEPH has emerged to be highly expressed not in the lung epithelium, as 275 functional partner of apically located FPN1, but on the endothelial cells of the lung vasculature and 276 in some perivascular cells (perycite/fibroblast cells). HEPH has been already identified on endothelial 277 cells of brain capillaries (30). In this context the ferroxidase has been shown to be localized on the 278 279 endothelium abluminal side, as well as on pervcites, where it is supposed to convert ferrous iron

released in the extracellular space by endothelial FPN1 into ferric iron, thus limiting oxidative damage. A similar mechanism could also operate in lung, where endothelial localized HEPH could similarly act on nutritional ferrous iron shipped in the interstitial space by FPN1, making it available for resident cell uptake, thus limiting oxidative damage. This precise architectural organization and functional interplay between endothelial cells, perycites and alveolare epithelial cells is compromised under pathological conditions such as cancer, and somehow reorganize to foster cancer cells proliferation.

Based on our bioinformatics analysis, further corroborated by immunohistochemistry, cancer 287 cells in LUAD and LUSC are mostly not expressing (LUAD) or poorly expressing, with a variable 288 degree, HEPH. This reduction is expected to limit FPN1-dependent iron export, which needs the 289 concomitant ferroxidase activity to fully function as a Fe^{2+} permease. The consequent increase in the 290 intracellular labile iron pool, via ROS generation, can stimulate cell proliferation and survival by 291 inducing several pro-survival signalling pathways and promote epithelial-to-mesenchymal transition 292 (EMT), an essential step for the initiation of metastasis. Innate immune cells and cancer-associated 293 294 fibroblasts are also a major source of iron and ROS in the tumour microenvironment (31).

According to TIMER bioinformatics analysis, HEPH expression has emerged to be strongly 295 296 and positively correlated with cancer associated fibroblasts (CAFs). Upon LUAD and LUSC specimens HEPH immunolabeling, we clearly identified HEPH expressing cells characterized by an 297 elongated spindle-shaped morphology typical of fibroblasts, enveloping some tumour nests in LUSC 298 cancer histotype. CAFs are the most dominant cellular component in the tumour stroma which not 299 only provide physical support to tumour cells but also play key role in promoting or hampering 300 tumorigenesis in a context-dependent manner. CAFs are highly heterogenous cell population due to 301 302 their multiple origins: they can arise from resident fibroblasts, bone marrow-derived progenitor cells or epithelial/endothelial cells that have undergone epithelial to mesenchymal transition. Cellular 303 trans-differentiation, both from stromal cell to stromal cell and from tumour cell to stromal cell have 304 all been described, being fibroblast trans-differentiation into activated myofibroblast, positive for α -305 SMA expression, the most frequently cited example. With the aim to better characterized our HEPH 306 307 positive stromal elements we performed HEPH/ α -SMA double-labelling experiments but we observe that a restricted minority of cells were for both antigens (data not shown). This observation raises the 308 possibility that these tumour-associated stromal elements could belong to the most aggressive "matrix 309 remodelling" subtypes, as classified by Marini and colleagues (21), which are characterized by 310 increased expression of fibroblast activating protein (FAP) but low expression of α -SMA. It is 311 interesting to note that FAP mRNA expression is the only marker emerged to be slightly upregulated, 312

even though not reaching a statistical significance, in LUAD and LUSC as compared to normal tissue
(Figure 4A). Further in-depth studies will be required to unravel all these issues.

As far as innate immunity is concern, neutrophils and macrophages, as detected by MPO and 315 CD14 immunoreactivity, were also identified as HEPH expressing cells infiltrating the tumour tissues 316 under investigation. Neutrophils, the hallmark of acute inflammation, have been shown to represent 317 a substantial proportion of the immune infiltrate in a wide variety of cancer types, including lung 318 cancer, even though their role is still debated (32). Tumour-associated neutrophils (TANs) could exert 319 a beneficial anti-tumour function, based on their high cytotoxic potential that could be directed toward 320 cancer cells (33). On the other hand, other studies support the notion that TANs would, instead, 321 promote tumour progression based on their ability to release angiogenic factors, and other mediators 322 able to stimulate cell motility, migration and invasion. Almost nothing is known regarding how 323 alteration in iron handling by neutrophils would impact on their activity in a tumoral context. These 324 325 cells utilize iron-dependent ROS production through a process called respiratory or oxidative burst and iron is required for both neutrophil NADPH oxidase and MPO activities as a component of the 326 327 catalytic site (34, 35). Under iron overload conditions, it has been shown that ROS production by neutrophils is significantly impaired (36). Since LUAD and LUSC infiltrating neutrophils express 328 329 HEPH, making them able to avoid intracellular iron overload, this may indicate that they are fully 330 competent to execute their cytotoxic potential, thus exerting an anti-tumour activity. They could also participate in iron clearance upon release of lactoferrin contained in their secondary granules. 331

In most malignancies tumor associated macrophages (TAM) are characterized by an iron-332 release phenotype required to sustain tumor growth and mediate immune suppression in the tumor 333 microenvironment (37). Recently it has been shown that TAMs exposed to hemolytic red blood cells, 334 event occurring upon extravasation of erythrocytes from newly formed vessels, can be reprogrammed 335 from M2-like into pro-inflammatory (M1-like) phenotype, thus able to kill tumour cells (38). 336 Interestingly these observations were performed on lung adenocarcinoma affected patients, further 337 underlying the complexity TAM phenotypes can acquire as a consequence of different 338 cytokine/chemokine composition found on the tumour niche. 339

In conclusion, our study has further underlined the complex, and still poorly understood, association existing between iron metabolism and the cancerogenic mechanisms operating in different organ landscape. Bioinformatics analysis, based on mRNA expression dataset, indicate HEPH as a novel potential prognostic biomarker for lung cancer pathologies. Up-regulation of HEPH in LUAD and LUSC correlates with a better out-come, but only from the full comprehension of the functional cross-talk occurring between the different cell types identified as HEPH-expressing cells and cancer cells will allow us to envision new therapeutic strategy to fight such devastating diseases.

347

348 ETHICS STATEMENT

- 349 This study was carried out in accordance with the Declaration of Helsinki and was approved by the
- University of Palermo Ethical Review Board (approval number 09/2018).
- 351

352 CONFLICT OF INTEREST

- 353 The author declare that they have no conflict of interest.
- 354

355 AUTHOR CONTRIBUTIONS

- 356 Conception and design: Paola Zacchi, Alessandro Mangogna and Violetta Borelli. Development of
- 357 methodology: Paola Zacchi, Alessandro Mangogna. Acquisition of data: Beatrice Belmonte, Letizia
- 358 Scola, Gaia Morello and Anna Martorana. Analysis and interpretation of data (e.g., statistical analysis,
- biostatistics, and computational analysis): Alessandro Mangogna, Paola Zacchi and Violetta Borelli.
- 360 Writing, review, and/or revision of the manuscript: Paola Zacchi, Alessandro Mangogna and Violetta
- 361 Borelli. Study supervision: Violetta Borelli.
- 362

363 FUNDINGS

- 364 This work was supported by grants from the Italian League for the Fight Against Cancer (LILT),
- 365 Gorizia section (Bando di Ricerca sanitaria 2017-programma 5 per mille anno 2015).
- 366

367 ACKNOWLEDGEMENTS

We thank prof. Giuliano Zabucchi for critical review of the manuscript and Dr. Armando Gentile forhis technical assistance.

- Table 1. Correlation analysis between HEPH expression and immune infiltration level of the
- indicated immune cells. The "Purity Adjustment" option was applied to all analysis performed.

	LUAD		LUSC	
	Rho	р	Rho	р
Purity	-0.341	6.3e-15	-0.343	1.21e-14
CD8+ T cell	0.184	3.9e-05	0.273	1.38e-09
CD4+ T cell	0.167	2.03e-04	0.233	2.55e-07
Macrophages	0.406	5.7e-21	0.206	5.89e-06
Neutrophis	0.285	1.03e-10	0.278	6.15e-10

Figures' legends 376

377

Figure 1. Pathological significance of HEPH expression in different types of human cancers and in-378 depth evaluation in LUAD and LUSC. (A) Human HEPH expression levels in different tumour types 379 from TCGA database were determined by TIMER (*P < 0.05, **P < 0.01, ***P < 0.001). (B) HEPH 380 mRNA expression comparisons between normal and tumour tissues were further obtained from the 381 GEPIA web tool. (C) HEPH protein expression comparison between normal and tumour tissues 382 obtained from the UALCAN web tool (Wilcoxon test). P-value < 0.05 was used to assess 383 differences.(D) Survival analyses of HEPH by Kaplan-Meier estimator with log-rank test obtained 384 from the Kaplan Meier plotter web tool. Survival differences are compared between patients with 385 high and low (grouped according to Auto select best cut-off) expression of HEPH. H, high expression; 386 L, low expression. 387

388

Figure 2. Correlation of HEPH expression with infiltration level of non-immune cells in LUAD and 389 390 LUSC. HEPH expression is significantly negatively related to tumour purity and has significant positive correlations with infiltrating levels of cancer-associated fibroblasts and endothelial cells. 391 392

Figure 3. HEPH expression positively correlated with markers of cancer-associated fibroblasts and 393 endothelial cells in both LUAD and LUSC. Scatterplots of correlations between HEPH and gene 394 markers include ACTA2, FAP, PDGFRA, PDGFRB for cancer-associated fibroblasts and PECAM1 395 (CD31) and vWF for endothelial cells. 396

397

Figure 4. Overall survival curve of each cancer-associated fibroblasts and endothelial marker shown 398 to correlate to HEPH expression and produced by Kaplan-Meier website resource. OS differences are 399 compared between patients with high and low (grouped according to Auto select best cut-off). H, 400 high expression; L, low expression. 401

402

Figure 5. HEPH distribution in "normal" lung. Representative microphotographs relative to HEPH 403 expression by the endothelial cells (red arrows), cells of the myelomonocyte lineage cells including 404 monocytes, macrophages, and granulocytes (black arrows) in "healthy" pulmonary parenchyma. 405 Original Magnification 20X (A) and 40X (B). 406

407

Figure 6. HEPH distribution in lung adenocarcinoma specimen. Representative microphotographs 408 relative to HEPH expression in two different lung adenocarcinoma affected patients (A-C and higher 409

magnification B-D). The tumour tissue is infiltrated by some HEPH positive myelomonocyte lineage
cells including monocytes, macrophages, and granulocytes (black arrows). Original Magnification
20X (A) and 40X (B).

413

Figure 7. HEPH distribution in lung squamous cell carcinoma specimen. Representative microphotographs relative to HEPH expression in two different lung squamous cell carcinoma affected patients (A-C and higher magnification B-D). The tumour tissue is infiltrated by some HEPH positive stromal elements (panel D, green arrows) and cells of the myelomonocyte lineage cells including monocytes, macrophages, and granulocytes (black arrows). Original Magnification 20X (A) and 40X (B).

420

421 **REFERENCES**

- Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung CancerClassifications *Ann Glob Health*.
 (2019) 85:1-16. doi: 10.5334/aogh.2419
- 424 2. Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO Classification. *Front* 425 Oncol. (2017) 7:193. doi: 10.3389/fonc.2017.00193
- 426 3. Lorelei de Jesus A, Rahman M, Mazaheri M, Thompson H, Knibbs LD, Jeong C, et al. Ultrafine particles and
 427 PM2.5in the air of cities around the world: Are they representative of each other? *Environment International*428 (2019) 129:118-135. doi.org/10.1016/j.envint.2019.05.021
- 4. Ying Chen, Zhimin Fan, Ye Yang, Chunyan Gu. Iron metabolism and its contribution to cancer. *International Journal of oncology* (2019) 54: 1143-1154
- 431 5. Cloonan SM, Mumby S, Adcock IM; Choi AMK, Chung KF, Quimlan GJ. The "Iron"-y of iron overload and
 432 iron deficiency in chronic obstructive pulmonary disease. *American Journal of respiratory and critical care*433 *medicine*. (2017) 196:1103-1112. doi: 10.1164/rccm.201702-0311PP
- 6. Ghio, A.J. Disruption of iron homeostasis and lung disease. Biochim. Biophys. Acta 2009, 1790:731–739.
 doi: 10.1016/j.bbagen.2008.11.004
- 436 7. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron
 437 metabolism. (2010) *Cell* 142:24-38. doi: 10.1016/j.cell.2010.06.028.
- 438 8. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ. Hephaestin, a
 439 ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet*440 (1999) 21:195-9. doi: 10.1038/5979.
- 9. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F,
 Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG1, implicated in
 the basolateral transfer of iron to the circulation. *Molecular Cell* (2000) 5:299-309 doi: 10.1016/s10972765(00)80425-6

445	10.	Yang F, Haile DJ, Wang X, Dailey LA, Stonehuerner JG, Ghio AJ. Apical location of ferroportin 1 in airway
446		epithelia and its role in iron detoxification in the lung. Am J Physiol Lung Cell Mol Physiol (2005) 289: L14 -
447		L23. doi.org/10.1152/ajplung.00456.2004
448	11.	Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. Cell Metabolism (2015) 22:P777-787
449		doi.org/10.1016/j.cmet.2015.09.006
450	12.	Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr., Kute T, Willingham MC, et al. Ferroportin and iron
451		regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 2:43ra56. doi:
452		10.1126/scisignal.3001127
453	13.	Crovella S, Bianco AM, Vuch J, Zupin L, Moura RR, Trevisan E, Schneider M, et al. Iron signature in
454		asbestos-induced malignant pleural mesothelioma: A population-based autopsy study. J Toxicol Environ
455		Health A (2016) 79:129-41. doi: 10.1080/15287394.2015.1123452.
456	14.	Celsi F, Crovella S, Moura RR, Schneider M, Vita F, Finotto L, Zabucchi G, Zacchi P, Borelli V. Pleural
457		mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism
458		and inflammation genes J Toxicol Environ Health A (2019) 82(20):1-15.
459		doi.org/10.1080/15287394.2019.1694612
460	15.	Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y, Geng M, Ding J, Chen Y. G9a regulates breast cancer
461		growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Front Genet. (2020)
462		11: 579636. doi: 10.3389/fgene.2020.579636
463	16.	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK,
464		Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.
465		Neoplasia (2017) 19: 649–658. doi: 10.1016/j.neo.2017.05.002
466	17.	Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression
467		profiling and interactive analyses. Nucleic Acids Research (2017) 45: W98-W102. doi: 10.1093/nar/gkx247
468	18.	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating
469		immune cells. Nucleic Acids Research (2020) 48:W509-W514. doi.org/10.1093/nar/gkaa407
470	19.	Weinstein JN, Collisson EA, Mills GB, Shaw KM, Ozenberger BA, Shmulevich KEI, Sander C, Stuart JM, and
471		Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat Genet.
472		(2013) 45: 1113–1120. doi:10.1038/ng.2764.
473	20.	An Y, Liu F, Chen Y, Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J
474		Cell Mol Med (2020) 24:13-24. Doi:10.1111/jcmm.14745
475	21.	Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key
476		contributors to the tumor microenvironment. Breast Cancer Research (2016) 18:84 doi 10.1186/s13058-016-
477		0740-2
478	22.	Nagy A, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular
479		carcinoma using expression data of independent datasets. Scientific Reports (2018) 8:9227
480	23.	Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr (2018) 38:97-
481		doi: 10.1146/annurev-nutr-082117-051732.
482	24.	Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined Total Genome Loss of
483		Heterozygosity Scan of Breast Cancer Stroma and Epithelium Reveals Multiplicity of Stromal Targets.
484		Cancer Research (2004) 64:7231-6. doi: 10.1158/0008-5472.CAN-04-2866

485	25.	Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Rønnov-Jessen L.
486		Epithelial to Mesenchymal Transition in Human Breast Cancer Can Provide a Nonmalignant Stroma. Am J
487		Pathol. (2003) 162: 391-402. doi: 10.1016/S0002-9440(10)63834-5.
488	26.	Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of Endothelial to Mesenchymal Transition
489		as a Source for Carcinoma-Associated Fibroblasts. Cancer Res. (2007) 67:10123-10128. doi: 10.1158/0008-
490		5472.CAN-07-3127
491	27.	Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based
492		Biology, Prevention, and Treatment. Front. Immunol. (2020) 11:1-21. doi.org/10.3389/fimmu.2020.00159
493	28.	Zhang V, Nemeth E, Kim A. Iron in lung pathology. Pharmaceuticals (2019) 12: 30. doi:
494		10.3390/ph12010030
495	29.	Harris ZL, Durley AP, Man Tk, Gitlin JD. Targeted gene disruption reveals an es-sential role for
496		ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. USA (1999) 96,10812-10817
497	30.	Burkhart A, Skjorringe T, Johnsen KB, Siupka P, Thomsen LB, Nielsen MS, Thomsen LL, Moos T.
498		Expression of iron-related proteins at the neurovascular unit supports reduction and reoxidation of iron from
499		transport through the blood-brain barrier. Mol Neurobiol (2016) 53:7237-7253 doi 10.1007/s12035-015-9582-
500		7
501	31.	Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An
502		Overview. Cancers (2019) 11(8): 1191 doi: 10.3390/cancers11081191
503	32.	Mukaida N; Sasaki S, Baba T. Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development
504		and Progression. Int. J. Mol. Sci. (2020) 21:3457. doi:10.3390/ijms21103457
505 506 507	33.	Fridlender ZG, Sun J, Kim S Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor- associated neutrophil phenotype by TGF- β : 'N1' versus 'N2' TAN," <i>Cancer Cell</i> (2009) 16:183–194. doi: 10.1016/j.ccr.2009.06.017
508	34.	Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med. (2013)
509		210:1283-1299.
510	35.	Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. (2004) 4:181-189
511	36.	Renassia C, Louis S, Cuvellier S, Boussetta N, Deschemin JC, Borderie D, Bailly K, et al. Neutrophils from
512		hereditary hemochromatosis patients are protected from iron excess and are primed. Blood Advances (2020) 4:
513		3853- 3863 doi.10.1182/bloodadvances.2020002198.
514	37.	Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou1 X. Tumor-Associated Macrophages: Recent Insights and
515		Therapies. Front Oncol. (2020) 10:188. doi: 10.3389/fonc.2020.00188
516	38.	Costa da Silva M, Breckwoldt MO, VinchiF, Correia MP, Stojanovic A, Thielmann CM, Meister M, et al.
517		Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Front Immunol. (2017) 8:1479. doi:
518		10.3389/fimmu.2017.01479



Low

High

Low

High

Low

High

medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250298; this version posted January 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in FIG user petraty. All rights reserved. No reuse allowed without permission.



Cancer associated fibroblasts markers А



В Endothelial cells markers





High 230

High High

medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250298; this version posted January 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the augulfuncter, who has granted medRxiv a license to display the preprint in perpetuity. ACTA2 All rights reserved. No reuse alR0xeffRr/thout permission. PDGFRB

В

Α

Figure 5



LUAD



LUSC

